Acrivon CHKs itself
The company is abandoning ovarian and bladder, but still sees a path in endometrial cancer.
AACR 2025 preview – Roche's TIGIT postmortem
Skyscraper-01 stars at AACR's upcoming clinical trial plenary.
Akeso keeps cadonilimab in China
The anti-PD-1 x CTLA-4 bispecific impresses in cervical cancer, but US plans are on ice.
Mural fails to paint a convincing picture for nemvaleukin
The Artistry-7 Keytruda combo trial fails, spurring discontinuation in ovarian cancer.
Pfizer dials down its atirmociclib ambitions
The company is stepping back in second-line breast cancer.
ELCC 2025 – J&J takes it to Tagrisso
The company talks up Rybrevant plus Lazcluze’s disease-modifying potential, but still has much to prove.
iTeos, and Roche's RAS mystery, start phase 1
First-in-human study listings include EOS-215 and RO7673396.
Summit looks to repeat ivo's Chinese success
Akeso scored in the Harmoni-A trial, and now Summit must do the same in Harmoni.
